VISEN Pharma Maintains Stable Share Capital in April 2026; Confirms Public-Float Compliance

Bulletin Express05-06

VISEN Pharmaceuticals (VISEN Pharma-B) filed its Monthly Return to Hong Kong Exchanges and Clearing for the period ended 30 April 2026, showing no movement in either authorised or issued share capital during the month.

• Authorised capital remained at 500.00 million ordinary shares with a par value of USD 0.0001 each, equivalent to USD 50,000.

• Issued share capital closed the month unchanged at 113.93 million ordinary shares; the company held no treasury shares.

• VISEN Pharma confirmed that its public float continues to satisfy the Main Board’s minimum 25% requirement.

• No share options, warrants, convertible securities or other equity instruments were issued, exercised, or redeemed in April.

• Under the Post-IPO Share Award Scheme adopted on 16 November 2022, no new shares were issued or transferred in the month, leaving capacity for up to 2.40 million shares to be granted in future.

The company’s disclosure indicates a stable capital structure, with all regulatory confirmations signed by Executive Director Lu An-Bang on 6 May 2026.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1141813215?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-05-06 16:23","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1141813215","market":"us","top_or_hot":-1,"title":"VISEN Pharma Maintains Stable Share Capital in April 2026; Confirms Public-Float Compliance","media":"Bulletin Express","content":"<p>VISEN Pharmaceuticals (VISEN Pharma-B) filed its Monthly Return to Hong Kong Exchanges and Clearing for the period ended 30 April 2026, showing no movement in either authorised or issued share capital during the month.</p>\n<p>• Authorised capital remained at 500.00 million ordinary shares with a par value of USD 0.0001 each, equivalent to USD 50,000.</p>\n<p>• Issued share capital closed the month unchanged at 113.93 million ordinary shares; the company held no treasury shares.</p>\n<p>• VISEN Pharma confirmed that its public float continues to satisfy the Main Board’s minimum 25% requirement.</p>\n<p>• No share options, warrants, convertible securities or other equity instruments were issued, exercised, or redeemed in April.</p>\n<p>• Under the Post-IPO Share Award Scheme adopted on 16 November 2022, no new shares were issued or transferred in the month, leaving capacity for up to 2.40 million shares to be granted in future.</p>\n<p>The company’s disclosure indicates a stable capital structure, with all regulatory confirmations signed by Executive Director Lu An-Bang on 6 May 2026.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>VISEN Pharma Maintains Stable Share Capital in April 2026; Confirms Public-Float Compliance</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nVISEN Pharma Maintains Stable Share Capital in April 2026; Confirms Public-Float Compliance\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time\">2026-05-06 16:23</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>VISEN Pharmaceuticals (VISEN Pharma-B) filed its Monthly Return to Hong Kong Exchanges and Clearing for the period ended 30 April 2026, showing no movement in either authorised or issued share capital during the month.</p>\n<p>• Authorised capital remained at 500.00 million ordinary shares with a par value of USD 0.0001 each, equivalent to USD 50,000.</p>\n<p>• Issued share capital closed the month unchanged at 113.93 million ordinary shares; the company held no treasury shares.</p>\n<p>• VISEN Pharma confirmed that its public float continues to satisfy the Main Board’s minimum 25% requirement.</p>\n<p>• No share options, warrants, convertible securities or other equity instruments were issued, exercised, or redeemed in April.</p>\n<p>• Under the Post-IPO Share Award Scheme adopted on 16 November 2022, no new shares were issued or transferred in the month, leaving capacity for up to 2.40 million shares to be granted in future.</p>\n<p>The company’s disclosure indicates a stable capital structure, with all regulatory confirmations signed by Executive Director Lu An-Bang on 6 May 2026.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02561","symbol_name":"维昇药业-B","start_time":0,"source_url":"","article_id":"1141813215","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1141813215","pubTimestamp":1778055795,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"VISEN Pharmaceuticals (VISEN Pharma-B) filed its Monthly Return to Hong Kong Exchanges and Clearing for the period ended 30 April 2026, showing no movement in either authorised or issued share...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"02561":"维昇药业-B"},"translate_title":"维森制药2026年4月股本保持稳定；确认公众持股合规性","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02561":1},"content_text":"VISEN Pharmaceuticals (VISEN Pharma-B) filed its Monthly Return to Hong Kong Exchanges and Clearing for the period ended 30 April 2026, showing no movement in either authorised or issued share capital during the month.\n• Authorised capital remained at 500.00 million ordinary shares with a par value of USD 0.0001 each, equivalent to USD 50,000.\n• Issued share capital closed the month unchanged at 113.93 million ordinary shares; the company held no treasury shares.\n• VISEN Pharma confirmed that its public float continues to satisfy the Main Board’s minimum 25% requirement.\n• No share options, warrants, convertible securities or other equity instruments were issued, exercised, or redeemed in April.\n• Under the Post-IPO Share Award Scheme adopted on 16 November 2022, no new shares were issued or transferred in the month, leaving capacity for up to 2.40 million shares to be granted in future.\nThe company’s disclosure indicates a stable capital structure, with all regulatory confirmations signed by Executive Director Lu An-Bang on 6 May 2026.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"shareholding,SGX","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.2","shortVersion":"4.42.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1141813215","isCrawlerRequest":true}